Acurex Biosciences moves 15-lipoxygenase program closer to Parkinson’s disease clinical testing
Parkinson’s drugs still treat symptoms. Acurex’s ASAP grant puts 15-lipoxygenase and ferroptosis into sharper disease-modifying focus.
Pharma & Biotech
Pharma & Biotech
Why everyone watching neurology at AAN 2026 may end up talking about Acadia Pharmaceuticals
Acadia Pharmaceuticals heads to AAN 2026 with Daybue, Nuplazid, and ACP-711 data. Read what the updates could mean for its neurology strategy.
Pharma & Biotech
Could Praxis Precision Medicines’ Phase 3 ulixacaltamide data redefine the treatment pathway in essential tremor?
Praxis Precision Medicines’ positive Phase 3 ulixacaltamide data could reshape essential tremor treatment. Discover what this means for neurology and investors.
Medical Devices & Diagnostics
Insightec’s focused ultrasound therapy secures French reimbursement. Could incisionless brain procedures expand across Europe?
France approves reimbursement for MR-guided focused ultrasound in essential tremor. Discover what the policy change means for neurosurgery and patient access.